Quark Biosciences and Personal Genomics forge the future of healthcare
- Unlocking the potential of gene sequencing to propel a new era of individualised care
Country Business Reports interviews and articles by Discovery Reports
The sequence of the human genome is arguably the most compelling data set the biomedical research community has ever known, according to a report by the United States National Centre for Biotechnology Information. Completed as early as 2003, its significance is just starting to unravel, most notably in the medical sector.
Using data from the Human Genome Project, an individual’s genetic profile can now be used to guide doctors and patients in making decisions regarding prevention, diagnosis and treatment of diseases, paving the way for more personalised medical treatments. Dismissing the one-size-fits-all approach to diagnostics and drug therapy, personalised medicine is an emerging field where Quark Biosciences (QuarkBio) plays a big part.
The Taiwan-based global provider of precision healthcare solutions is keen on sharing its knowledge and experience in real-time diagnostics to save lives. An offshoot of the successful convergence of the world’s leading physicians and first-rate researchers of biotechnology company Personal Genomics, QuarkBio develops innovative precision oncology, fertility treatment, and disease diagnostics and prevention products.
From research to the patient
Applied alongside clinical examinations, QuarkBio’s healthcare solutions are based on the latest research findings combined with the needs of doctors and patients. As a result, these high-quality precision medical solutions improve a patient’s quality of life without the financial burden of long-term care.